TopAlliances’ Dydrogesterone Tablets Approved for General Use
January 15, 2025
Source: drugdu
32
Beijing Business News (Reporter Ding Ning) - On the evening of January 12, TopAlliances (688180) announced that its wholly-owned subsidiary, Shanghai Wangshi Biopharmaceutical Technology Co., Ltd., has received a "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration (NMPA). The hydrochloride of Dydrogesterone Tablets (brand name: Mindev) for the treatment of adult patients with mild to moderate COVID-19 infection has been approved by the NMPA, transitioning from conditional approval to general approval.
https://finance.eastmoney.com/a/202501123294345292.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- 2025 medical device global exhibition summary January 15, 2025
- 2025 Biopharmaceutical global exhibition summary January 15, 2025
- IPO Radar | Losing 1 billion yuan in one year, Maiwei Biotechnology seeks A+H listing, how long can it survive relying on external “blood transfusion”? January 15, 2025
- Johnson&Johnson’s new drug, Edatinib, has been approved for market in China | Medical Early Reference January 15, 2025
- United Imaging Medical, there are big moves in North America January 15, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
